The Dense Breast Problem: What Every Woman Needs to Know

Breast density refers to the amount of fibrous and glandular tissue in the breast compared to fatty tissue. On a mammogram, both dense tissue and tumors appear white - making it extraordinarily difficult to distinguish between the two.

The numbers tell a striking story:

• Approximately 40-50% of women have dense breast tissue, according to the FDA and the American Cancer Society (ACS, 2024).
• Women with dense breasts have a 15-20% greater risk of developing breast cancer and a higher likelihood of a false-negative mammogram (American Cancer Society, 2024).
• Mammography sensitivity drops from 93% in women with fatty breasts to as low as 30% in women with extremely dense breasts, according to research published in RadioGraphics, the journal of the Radiological Society of North America (Lee et al., 2024).
• About 40% of breast cancers go undetected on mammography in women with the densest breast tissue (University of Pittsburgh Medical Center / UPMC, 2023).

Put plainly: if you have dense breasts and rely on mammography alone, nearly one in three or more of your cancers could be missed.

‍

Why Mammography Alone Isn't Enough for Dense Breasts

Mammography has been the gold standard of breast cancer screening for decades and it has saved lives. But its structural limitation when applied to dense tissue is well established in the literature.

A landmark study published in RadioGraphics (2024) found that with increasing breast density, not only does mammographic sensitivity plummet, but the rate of false positives increases: from 11 false positives per 1,000 examinations in fatty breasts to 24 per 1,000 in extremely dense breasts. That means more unnecessary callbacks, more anxiety, more biopsies, and more healthcare costs - without the payoff of accurate detection.

A 2025 study from Oregon Health & Science University (OHSU), published in the American Journal of Epidemiology, confirmed that digital mammography sensitivity is 73% for women with extremely dense breasts, compared with 93% for women with mostly fatty breasts. The research also found that dense breast tissue increases the risk of a breast cancer diagnosis by 1.8 times.

Research on the Dutch national breast screening program showed that mammography reduced the relative risk of breast cancer death by 41% in women with fatty breasts - but only 13% in women with dense breasts. For women with dense breast tissue, the most widely used cancer screening tool offers a fraction of its intended benefit.

The FDA recognized this gap. In September 2024, a landmark new rule took effect requiring that all mammography facilities nationwide notify patients if their breast tissue is dense and inform them explicitly: "Dense tissue makes it both harder to find breast cancer on a mammogram and raises the risk of developing breast cancer." The rule also states that other imaging tests may help find cancers, officially opening the door to supplemental screening.

‍

The Stakes: Why Early Detection Is Everything

Breast cancer caught early is overwhelmingly survivable. According to the American Cancer Society's Breast Cancer Facts & Figures 2024-2025, when breast cancer is detected at the localized stage, the 5-year survival rate exceeds 99%. When it has spread regionally, that rate drops to 86%. When caught at a distant (metastatic) stage, it falls to 31%.

This is why the detection gap for women with dense breasts isn't just a statistical inconvenience - it is a matter of life and death. Cancers that go undetected in dense tissue are not found earlier; they are found later, when treatment is more aggressive, outcomes are worse and survival is far less certain.

‍

Enter QTI: A Fundamentally Different Way to See the Breast

Quantitative Transmission Imaging (QTI), the technology behind the QT Imaging Breast Acoustic CT™ Scanner, was developed precisely to solve this problem. And it does so in a way that is not only more effective for dense breasts, but safer and more comfortable for every patient.

‍

What Is QTI?

QTI is a 3D ultrasound tomography technology that uses low-frequency sound waves, not X-rays, to create detailed volumetric images of the entire breast. A 360-degree ring transducer captures both transmission-mode and reflection-mode ultrasound data simultaneously, generating quantitative 3D maps of breast tissue composition, density, stiffness, and structure.

Because sound waves pass through dense tissue rather than being blocked by it the way X-rays are, QTI can see what mammography cannot. Dense tissue is no longer a white wall obscuring potential tumors: it becomes navigable, differentiated, and diagnostic.

‍

FDA-Cleared and Clinically Validated

The QT Imaging Breast Acoustic CT™ Scanner holds FDA 510(k) clearance as a supplemental breast imaging device for women 18 years and older, including for follow-up of inconclusive or suspicious mammogram findings. It is also cleared for quantitative assessment of fibroglandular tissue volume and breast density - the first ultrasound-based technology to receive this clearance.

In March 2026, QT Imaging received an additional FDA 510(k) clearance for an enhanced scanner configuration that improves visualization and expands coverage of posterior breast tissue near the chest wall, one of the most difficult areas to image with standard approaches.

‍

The Clinical Evidence

The science backing QTI is robust and peer-reviewed:

Study 1 (2020) Academic Radiology: An exploratory multi-reader, multi-case study comparing QTI's performance directly with mammography found QTI to be competitive with, and in some measures superior to, standard mammography for breast cancer detection and recall rates.

Study 2 (2024) Academic Radiology: A second blinded multi-reader, multi-case study involving 24 breast radiologists and 177 selected cases (including 66 with cancer, atypia, or solid mass) found that QTI's Breast Acoustic CT is non-inferior to digital breast tomosynthesis (DBT) - also known as 3D mammography, the current clinical benchmark - in detecting and recalling breast lesions. The area under the ROC curve (AUC) was statistically equivalent between the two modalities.

Patient-Reported Outcomes (2024) PMC / National Institutes of Health: A peer-reviewed study on patient experience confirmed that the QT Breast Scan is not only clinically non-inferior to mammography, but significantly better tolerated, with higher patient satisfaction scores, lower reported discomfort and fewer concerns about the imaging experience.

‍

Why QTI Is the Preferred Supplemental Screening for Dense Breasts

1. It Sees Through Dense Tissue

This is the fundamental advantage. Where mammography treats dense tissue as visual noise that obscures tumors, QTI's sound-wave technology differentiates tissue types based on their acoustic properties: density, speed of sound, and attenuation. Tumors and dense fibroglandular tissue have different acoustic signatures, allowing radiologists to identify lesions that would be invisible on a mammogram.

2. Zero Radiation

The QT Breast Acoustic CT Scanner uses low-frequency sound waves, there is no ionizing radiation whatsoever. This makes it safe for frequent monitoring, ideal for younger women who may not yet be eligible for routine mammography, and appropriate for women who need ongoing surveillance due to elevated risk. Women with BRCA1 or BRCA2 mutations, for example, face a 40-85% lifetime risk of breast cancer (QT Imaging / FDA Breakthrough Device Designation, 2018) and may benefit significantly from a radiation-free imaging option that can be repeated without cumulative risk.

3. No Painful Compression

Mammography requires the breast to be compressed between two plates: a process many women describe as painful and that actively deters some from returning for routine screenings. The QT Breast Acoustic CT requires no compression. The patient places her breast in a water bath while the 360° transducer acquires images - painlessly, comfortably, and without deformation of tissue.

4. True 3D Volumetric Imaging

Unlike conventional 2D mammography (which relies on overlapping projections) or even 3D tomosynthesis (which reconstructs from 2D slices), QTI generates true volumetric 3D data. This eliminates the projection overlap that can cause dense tissue to either obscure a lesion or mimic one, reducing both false negatives and false positives.

5. Quantitative Biomarkers and AI Integration

QTI doesn't just produce images. It generates measurable, quantitative biomarkers including fibroglandular tissue volume (FGV) and the ratio of fibroglandular tissue to total breast volume (TBV). These metrics support breast density assessment, therapy monitoring, and risk stratification. QT Imaging's cloud-connected AI platform continuously refines cancer probability mapping algorithms; meaning the technology becomes more precise over time.

6. Safe for Younger, High-Risk Women

Routine mammography is not recommended for women under 40. But breast cancer doesn't wait - approximately 16% of women diagnosed with breast cancer in 2024 were under 50 (Breastcancer.org / ACS, 2024), and younger women with BRCA mutations or strong family histories face serious risk well before the mammography screening age. QTI is cleared for women 18 and older, filling a critical gap for younger high-risk patients who currently have limited screening options.

7. Fewer False Positives, Less Unnecessary Anxiety

One of mammography's most burdensome shortcomings is its high rate of false positives in dense breasts - leading to callback appointments, additional imaging, and biopsies for findings that turn out to be benign. QTI's higher specificity means fewer unnecessary recalls, less patient anxiety and reduced downstream healthcare costs.

Who Should Consider QTI Supplemental Screening?

QTI breast screening may be particularly valuable for women who:

• Have been told they have dense or extremely dense breast tissue (BI-RADS C or D)
• Have a family history of breast cancer
• Carry a BRCA1 or BRCA2 genetic mutation or other hereditary risk factor
• Are under 40 and at elevated risk but not yet eligible for routine mammography
• Have had inconclusive or suspicious mammogram results requiring follow-up
• Cannot tolerate MRI (due to claustrophobia, implants, or other contraindications)
• Are pregnant or trying to conceive and need a radiation-free option
• Simply want a more comfortable, comprehensive screening experience

‍

Qlarity Breast Imaging NY: Bringing QTI to New York Women

At Qlarity Breast Imaging NY, we believe that every woman deserves screening that can actually see her. For too long, women with dense breasts have been told their mammograms are "normal" while cancers go undetected. We are committed to changing that - with technology that is scientifically validated, FDA-cleared, radiation-free and designed for the way women's bodies actually work.

If you have dense breast tissue, a family history of breast cancer, or simply want the most thorough screening available, we invite you to learn more about QTI at Qlarity Breast Imaging NY.

Every woman deserves clarity and comfort.